Wire · opportunities
FDA final guidance on psychedelics opens the door to psycho-oncology research
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 July 2026 · Fusion42 review
FDA released final guidance for psychedelic drug trials (psilocybin, LSD, MDMA) in psychiatric and substance abuse disorders, permitting treatment without mandatory psychotherapy—a regulatory shift that opens psycho-oncology research pathways.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
If you're running psychedelic trials for cancer patients, you no longer need to build psychotherapy into your protocol—FDA just cut a regulatory cost and complexity barrier that was keeping smaller teams out. The door to psycho-oncology is now open; the question is which established oncology player moves first.
◆ Coverage
1 source · 17 Jul 2026
◆ Related on Wire
◆ Topics